@article{2adcc18585734fcd9a6efd7fad1e50f3,
title = "PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0",
abstract = "Here we aim to provide updated guidance and standards for the indication, acquisition, and interpretation of PSMA PET/ CT for prostate cancer imaging. Procedures and characteristics are reported for a variety of available PSMA small radioligands. Different scenarios for the clinical use of PSMA-ligand PET/CT are discussed. This document provides clinicians and technicians with the best available evidence, to support the implementation of PSMA PET/CT imaging in research and routine practice.",
keywords = "PSMA, PET, Prostate cancer, Staging, Restaging, Guideline, MEMBRANE ANTIGEN PSMA, LU-177-PSMA-617 RADIOLIGAND THERAPY, RADIATION-DOSIMETRY, BIOCHEMICAL RECURRENCE, GA-68-PSMA PET/CT, F-18-DCFPYL PET/CT, EXPRESSION, BIODISTRIBUTION, DIAGNOSIS, RECOMMENDATIONS",
author = "W.P. Fendler and M. Eiber and M. Beheshti and J. Bomanji and J. Calais and F. Ceci and S.Y. Cho and S. Fanti and F.L. Giesel and K. Goffin and U. Haberkorn and H. Jacene and P.J. Koo and K. Kopka and B.J. Krause and L. Lindenberg and C. Marcus and F.M. Mottaghy and D.E. Oprea-Lager and J.R. Osborne and M. Piert and S.P. Rowe and H. Schoder and S. Wan and H.J. Wester and T.A. Hope and K. Herrmann",
note = "Funding Information: The authors thank the EANM and SNMMI committees and national societies for their critical review of the manuscript: EANM Radiopharmaceuticals Sciences committee, EANM Radiation Protection committee, EANM Bone & Joint committee, EANM Technologists committee, EANM Oncology & Theranostic committee, EANM Physics committee, EANM Dosimetry committee; National Societies: Slovenia, Finland, Denmark, Italy, Netherlands, Germany, Romania, Czech Republic, Sweden, Poland, North Macedonia, United Kingdom, Hungary, Portugal, Slovak Republic, Estonia, Serbia, and Croatia. We also appreciate the great support from EANM office in Vienna and the SNMMI office in Reston, Virginia, during the development of this guideline. Funding Information: T.H. reports fees from Clovis Oncology (research funding), Philips (research funding), GE Healthcare (research funding), Lantheus (research funding), the Prostate Cancer Foundation (research funding), the National Cancer Institute (research funding; R01CA235741 and R01CA212148), Ipsen (advisory board), Bayer (advisory board), BlueEarth Diagnostics (advisory board), RayzeBio (consultant and equity interest), and Curium (consultant and equity interest). Funding Information: D.E.O.-L. reports unrestricted grants from Janssen for Consensus meetings attendance outside the submitted work. Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = apr,
doi = "10.1007/s00259-022-06089-w",
language = "English",
volume = "50",
pages = "1466--1486",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer, Cham",
number = "5",
}